By Senator Book

32-00939-18 2018710

A bill to be entitled

An act relating to the Prescription Drug Donation Program; amending s. 499.029, F.S.; renaming the Cancer Drug Donation Program as the Prescription Drug Donation Program; authorizing the donation of prescription drugs, including cancer drugs, and supplies to eligible patients; revising definitions; authorizing nursing home facilities to participate in the program; providing an effective date.

10 11

1

2

3

4

5

6

7

8

9

Be It Enacted by the Legislature of the State of Florida:

1213

Section 1. Section 499.029, Florida Statutes, is amended to read:

1415

499.029 Prescription Cancer Drug Donation Program.-

1617

(1) This section may be cited as the " $\underline{\text{Prescription}}$ Cancer Drug Donation Program Act."

1819

20

(2) There is created a <u>Prescription Gancer</u> Drug Donation Program within the department for the purpose of authorizing and facilitating the donation of <u>prescription gancer</u> drugs and supplies to eligible patients.

2122

(3) As used in this section:

2324

25

2627

28

29

(a) "Cancer drug" means a prescription drug that has been approved under s. 505 of the Federal Food, Drug, and Cosmetic Act and is used to treat cancer or its side effects or is used to treat the side effects of a prescription drug used to treat cancer or its side effects. The term "Cancer drug" does not include a substance listed in Schedule II, Schedule III, Schedule IV, or Schedule V of s. 893.03.

32-00939-18 2018710

(b) "Closed drug delivery system" means a system in which the actual control of the unit-dose medication package is maintained by the facility rather than by the individual patient.

- (c) "Donor" means a patient or patient representative who donates prescription cancer drugs or supplies needed to administer prescription cancer drugs that have been maintained within a closed drug delivery system; health care facilities, nursing home facilities homes, hospices, or hospitals with closed drug delivery systems; or pharmacies, drug manufacturers, medical device manufacturers or suppliers, or wholesalers of drugs or supplies, in accordance with this section. The term "Donor" includes a physician licensed under chapter 458 or chapter 459 who receives prescription cancer drugs or supplies directly from a drug manufacturer, wholesale distributor, or pharmacy.
- (d) "Eligible patient" means a person who the department determines is eligible to receive <u>prescription</u> cancer drugs from the program.
- (e) "Participant facility" means a hospital that operates a class II institutional hospital pharmacy or a nursing home facility licensed under part II of chapter 400 with a closed drug delivery system that has elected to participate in the program and that accepts donated prescription cancer drugs and supplies under the rules adopted by the department for the program.
- (f) "Prescribing practitioner" means a physician licensed under chapter 458 or chapter 459 or any other medical professional with authority under state law to prescribe

32-00939-18 2018710

prescription drugs cancer medication.

- (g) "Prescription drug" has the same meaning as provided in s. 499.003, and includes cancer drugs.
- $\underline{\text{(h)}}$ "Program" means the <u>Prescription</u> Cancer Drug Donation Program created by this section.
- <u>(i) (h) "Supplies" means any supplies used in the administration of a prescription cancer drug.</u>
- (4) Any donor may donate <u>prescription cancer</u> drugs or supplies to a participant facility that elects to participate in the program and meets criteria established by the department for such participation. <u>Prescription Cancer</u> drugs or supplies may not be donated to a specific <u>cancer</u> patient, and donated drugs or supplies may not be resold by the program. <u>Prescription Cancer</u> drugs billed to and paid for by Medicaid in long-term care facilities that are eligible for return to stock under federal Medicaid regulations shall be credited to Medicaid and are not eligible for donation under the program. A participant facility may provide dispensing and consulting services to individuals who are not patients of the hospital <u>or nursing home facility</u>.
- (5) The <u>prescription</u> cancer drugs or supplies donated to the program may be prescribed only by a prescribing practitioner for use by an eligible patient and may be dispensed only by a pharmacist.
- (6) (a) A <u>prescription</u> cancer drug may only be accepted or dispensed under the program if the drug is in its original, unopened, sealed container, or in a tamper-evident unit-dose packaging, except that a <u>prescription</u> cancer drug packaged in single-unit doses may be accepted and dispensed if the outside

32-00939-18 2018710

packaging is opened but the single-unit-dose packaging is unopened with tamper-resistant packaging intact.

- (b) A <u>prescription</u> cancer drug may not be accepted or dispensed under the program if the drug bears an expiration date that is less than 6 months after the date the drug was donated or if the drug appears to have been tampered with or mislabeled as determined in paragraph (c).
- (c) Prior to being dispensed to an eligible patient, the prescription cancer drug or supplies donated under the program shall be inspected by a pharmacist to determine that the drug and supplies do not appear to have been tampered with or mislabeled.
- (d) A dispenser of donated <u>prescription</u> cancer drugs or supplies may not submit a claim or otherwise seek reimbursement from any public or private third-party payor for donated <u>prescription</u> cancer drugs or supplies dispensed to any patient under the program, and a public or private third-party payor is not required to provide reimbursement to a dispenser for donated <u>prescription</u> cancer drugs or supplies dispensed to any patient under the program.
- (7) (a) A donation of <u>prescription</u> cancer drugs or supplies shall be made only at a participant facility. A participant facility may decline to accept a donation. A participant facility that accepts donated <u>prescription</u> cancer drugs or supplies under the program shall comply with all applicable provisions of state and federal law relating to the storage and dispensing of the donated prescription cancer drugs or supplies.
- (b) A participant facility that voluntarily takes part in the program may charge a handling fee sufficient to cover the

32-00939-18 2018710

cost of preparation and dispensing of <u>prescription</u> cancer drugs or supplies under the program. The fee shall be established in rules adopted by the department.

- (8) The department, upon the recommendation of the Board of Pharmacy, shall adopt rules to carry out the provisions of this section. Initial rules under this section shall be adopted no later than 90 days after the effective date of this act. The rules shall include, but not be limited to:
- (a) Eligibility criteria, including a method to determine priority of eligible patients under the program.
- (b) Standards and procedures for participant facilities that accept, store, distribute, or dispense donated <u>prescription</u> cancer drugs or supplies.
- (c) Necessary forms for administration of the program, including, but not limited to, forms for use by entities that donate, accept, distribute, or dispense <u>prescription</u> cancer drugs or supplies under the program.
- (d) The maximum handling fee that may be charged by a participant facility that accepts and distributes or dispenses donated prescription cancer drugs or supplies.
- (e) Categories of <u>prescription</u> cancer drugs and supplies that the program will accept for dispensing; however, the department may exclude any drug based on its therapeutic effectiveness or high potential for abuse or diversion.
- (f) Maintenance and distribution of the participant facility registry established in subsection (10).
- (9) A person who is eligible to receive <u>prescription</u> cancer drugs or supplies under the state Medicaid program or under any other prescription drug program funded in whole or in part by

32-00939-18 2018710

the state, by any other prescription drug program funded in whole or in part by the Federal Government, or by any other prescription drug program offered by a third-party insurer, unless benefits have been exhausted, or a certain prescription cancer drug or supply is not covered by the prescription drug program, is ineligible to participate in the program created under this section.

- (10) The department shall establish and maintain a participant facility registry for the program. The participant facility registry shall include the participant facility's name, address, and telephone number. The department shall make the participant facility registry available on the department's website to any donor wishing to donate prescription cancer drugs or supplies to the program. The department's website shall also contain links to prescription cancer drug manufacturers that offer drug assistance programs or free medication.
- (11) Any donor of <u>prescription</u> cancer drugs or supplies, or any participant in the program, who exercises reasonable care in donating, accepting, distributing, or dispensing <u>prescription</u> cancer drugs or supplies under the program and the rules adopted under this section shall be immune from civil or criminal liability and from professional disciplinary action of any kind for any injury, death, or loss to person or property relating to such activities.
- (12) A pharmaceutical manufacturer is not liable for any claim or injury arising from the transfer of any <u>prescription</u> cancer drug under this section, including, but not limited to, liability for failure to transfer or communicate product or consumer information regarding the transferred drug, as well as

176

177

178179

180

32-00939-18 2018710__

the expiration date of the transferred drug.

(13) If any conflict exists between the provisions in this section and the provisions in this chapter or chapter 465, the provisions in this section shall control the operation of the Prescription Cancer Drug Donation Program.

Section 2. This act shall take effect July 1, 2018.